Quantcast

Latest Tyrosine kinase inhibitors Stories

2010-06-07 08:14:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001).

2010-06-06 07:50:04

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy.

2010-06-06 07:45:27

Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication.

2010-06-06 07:28:27

Combination of targeted agent, chemotherapy improves progression-free survival; therapy inhibits both VEGFR and EGFR.

2010-06-04 00:23:00

EAST HANOVER, N.J., June 4 /PRNewswire/ -- Novartis announced today 18-month results (median follow-up) showing that Tasigna® (nilotinib) capsules significantly surpass the efficacy of Gleevec® (imatinib mesylate) tablets* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1).

2010-05-20 17:00:00

SUNNYVALE, Calif., May 20 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the abstract it submitted for the Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8, 2010 in Chicago, IL was released by ASCO today.

2010-05-20 07:00:00

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets.

2010-05-17 12:40:39

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia.

2010-05-01 08:52:54

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable.

2010-04-30 13:26:21

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work.


Word of the Day
metagrabolized
  • totally perplexed and mixed up.
The word 'metagrabolized' is also spelled 'metagrobolized'.
Related